Amgen: upcoming dates

Recent

• Business10/04/2026@EconDesk

  Amgen Q2 2026: Revenue Up 10% to US$10.1 Billion

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 08/04/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better63 days agoAmgen's^[1] press release is datelined Thousand Oaks, Aug. 4, 2026; the SEC^[2][4] 8-K earnings exhibit carries the same date.

  On 4 August 2026 Amgen reported second-quarter revenue up 10% to US$10.1 billion, with GAAP EPS of US$4.37 and non-GAAP EPS of US$6.29, as 22 products grew at double-digit rates.

  00
• Health10/04/2026@HealthDesk

  FDA Proposes to Withdraw Amgen's Tavneos Approval

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 04/27/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better162 days agoAmgen's^[1][4] 10-Q for the quarter to 30 June 2026 states 'On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS'; Amgen's Tavneos update page confirms the proposal.

  On 27 April 2026 the FDA's drug centre issued a proposal to withdraw approval of Amgen's Tavneos for ANCA-associated vasculitis, alleging lack of substantial evidence of effectiveness; Amgen disagrees and the drug stays on the market.

  00
• Health10/04/2026@HealthDesk

  MariTide Phase 2: Up to 20% Weight Loss at 52 Weeks

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 11/26/2024CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better1.9 years agoAmgen's^[1] release is datelined Thousand Oaks, Nov. 26, 2024; ConsultantLive^[4] published its report on 26 November 2024.

  On 26 November 2024 Amgen reported 52-week Phase 2 data for its monthly obesity candidate MariTide, with up to about 20% average weight loss without a plateau, and announced the MARITIME Phase 3 program.

  00
• Business10/04/2026@EconDesk

  Amgen Completes US$27.8 Billion Horizon Therapeutics Deal

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 10/06/2023CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins84% CONFIDENCEOverall confidence: 84%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better3.0 years agoAmgen's^[1] release is datelined Thousand Oaks, Oct. 6, 2023; PharmExec^[3] and SoCalTech^[4] both dated their reports 6 October 2023.

  On 6 October 2023 Amgen completed its acquisition of Horizon Therapeutics for US$116.50 per share in cash, a transaction equity value of about US$27.8 billion that added Tepezza, Krystexxa and Uplizna.

  $27.8B

  00
• Health10/04/2026@HealthDesk

  FDA Approves Amgen's Epogen, Its First Product

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 06/01/1989CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins80% CONFIDENCEOverall confidence: 80%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better37.3 years agoAmgen's^[1] own history page and FundingUniverse's^[2] company history both give 1 June 1989 as the FDA approval date.

  On 1 June 1989 the FDA approved Epogen (epoetin alfa), Amgen's recombinant erythropoietin for anemia in kidney dialysis patients, its first product after nine years in business.

  00